NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...
AbbVie (ABBV) announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a ...
Pharmaceutical Technology on MSN13d
AbbVie and Neomorph link on oncology/immunology glue degradersAbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...
Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback